Limits...
Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.

Rezende FA, Lapalme E, Qian CX, Smith LE, SanGiovanni JP, Sapieha P - Am. J. Ophthalmol. (2014)

Bottom Line: Secondary outcomes were plasma VEGF-A and central foveal thickness.Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 ± 61.89 pg/mL) when compared with group 2 (626.09 ± 279.27 pg/mL; P = .036) and group 3 (735.48 ± 216.43 pg/mL; P = .013), but similar levels to group 4 (235.81 ± 33.99 pg/mL; P = .215).This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: frezendef@hotmail.com.

Show MeSH

Related in: MedlinePlus

Graph showing omega-3 supplementation and central foveal thickness in wet age-related macular degeneration and control patients. Assesment of central foveal thickness showed no significant difference between group 1 (anti–vascular endothelial growth factor [VEGF] plus omega-3) and group 2 (anti-VEGF alone; P=.2108), group 3 (treatment naïve, starting on anti-VEGF; P = .1511), and group 4 (control; P = .9579, t test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4389631&req=5

Figure 4: Graph showing omega-3 supplementation and central foveal thickness in wet age-related macular degeneration and control patients. Assesment of central foveal thickness showed no significant difference between group 1 (anti–vascular endothelial growth factor [VEGF] plus omega-3) and group 2 (anti-VEGF alone; P=.2108), group 3 (treatment naïve, starting on anti-VEGF; P = .1511), and group 4 (control; P = .9579, t test).

Mentions: Analysis of plasma levels of VEGF-A revealed no significant change between groups (P = .736; Figure 3). Similarly, although values for CFT tended toward improvement, no significant benefit was noted with omega-3 supplementation in the sample population investigated in this pilot study (P = .211; Figure 4).


Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.

Rezende FA, Lapalme E, Qian CX, Smith LE, SanGiovanni JP, Sapieha P - Am. J. Ophthalmol. (2014)

Graph showing omega-3 supplementation and central foveal thickness in wet age-related macular degeneration and control patients. Assesment of central foveal thickness showed no significant difference between group 1 (anti–vascular endothelial growth factor [VEGF] plus omega-3) and group 2 (anti-VEGF alone; P=.2108), group 3 (treatment naïve, starting on anti-VEGF; P = .1511), and group 4 (control; P = .9579, t test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4389631&req=5

Figure 4: Graph showing omega-3 supplementation and central foveal thickness in wet age-related macular degeneration and control patients. Assesment of central foveal thickness showed no significant difference between group 1 (anti–vascular endothelial growth factor [VEGF] plus omega-3) and group 2 (anti-VEGF alone; P=.2108), group 3 (treatment naïve, starting on anti-VEGF; P = .1511), and group 4 (control; P = .9579, t test).
Mentions: Analysis of plasma levels of VEGF-A revealed no significant change between groups (P = .736; Figure 3). Similarly, although values for CFT tended toward improvement, no significant benefit was noted with omega-3 supplementation in the sample population investigated in this pilot study (P = .211; Figure 4).

Bottom Line: Secondary outcomes were plasma VEGF-A and central foveal thickness.Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 ± 61.89 pg/mL) when compared with group 2 (626.09 ± 279.27 pg/mL; P = .036) and group 3 (735.48 ± 216.43 pg/mL; P = .013), but similar levels to group 4 (235.81 ± 33.99 pg/mL; P = .215).This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: frezendef@hotmail.com.

Show MeSH
Related in: MedlinePlus